• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

The Reasons to Be in AbbVie: Valuation, Dividend Yield, Confidence in Guidance

I have always liked the aggressive management.
By STEPHEN GUILFOYLE
May 11, 2020 | 10:43 AM EDT
Stocks quotes in this article: ABBV, ABT, AGN, JNJ, NSRGF, AZN

Long time coming. The road traveled seemed long, very long. How long ago was it that we were writing about how much we liked the aggression shown by AbbVie (ABBV) management in addressing the threat posed by the the expiration of patents concerning Humira, the firms' leading selling product. Humira, a treatment for rheumatoid arthritis, Crohn's disease, and a number of other maladies, has been the firm's cash cow, really since the split from Abbot Laboratories (ABT) back in early 2013. What AbbVie had done, about a year ago now, was address the potential hole in cash flow potentially created by generic competition for Humira, and to proceed with a deal to acquire Allergan (AGN) , another cash flow machine, with a cash cow of its own in Botox.

May 2020

The action, after barely moving for all that time, really picked up as April turned into May. First AbbVie reported the firm's first quarter results. Earnings beat expectations, adjusted or not. Revenue also beat, while showing better than 10% annual growth. Best pace of revenue generation for the firm since mid-2018. Best sellers? Humira of course, accounted for $4.703 billion worth of sales, or nearly 55% of the entire pie. Good for growth of 5.8%, even if the European patent had already expired and sales slowed there. Growth was still good in the U.S., however, where the similar patent does not expire until 2023.

Next up was Imbuvica, a cancer drug that the firm shares rights to with Johnson & Johnson (JNJ) . That newer entry produced sales of $1.232 billion for growth of 20.6%. AbbVie even guided, which has become kind of special this reporting season. AbbVie sees adjusted EPS (sans AGN) for the second quarter of $2.10 to $2.16, and for the full year of $9.61 to $9.71. First quarter performance was strong, but also past history. Early last week, Health Canada approved the firm's Velenclexta to be combined with Roche's (RHHBY) Gazyva for the treatment of lymphocytic leukemia. That same day, the firm finally received FTC (Federal Trade Commission) clearance to proceed with the Allergan deal, of course there was some hair on the approval, but that was largely expected.

Such A Deal

The deal, long time coming as it was, finally reached completion this past Friday evening. Allergan would not trade again, as a stand alone stock. Holders of that stock were to receive $120.30 in cash, and 0.866 share of ABBV in exchange for each share of AGN. In order to get the deal on the tape, Abbvie had to borrow $30 million in unsecured notes late last year. in addition, AbbVie has to divest Zenpep (cystic fibrosis) to Nestle  (NSRGF) , and Allergan had to divest brazikumab (autoimmune disease) to AstraZeneca (AZN) .

My Thoughts

Prior to the pandemic, sales of Humira had been expected to land in the neighborhood of $19 billion this year, and roughly $18 billion next year. Allergan, as a stand alone company produces $15 billion to $16 billion per year, roughly $4 billion give or take, from Botox. Given that as the generics move into Humira's space in 2023, it appears to me that AbbVie has more than plugged that hole, as I find it unlikely that Humira sales drop to zero.

While debt levels are now elevated in comparison to the firm's competitors, cash flow has in my view been protected. That makes the annual dividend of $4.72 (5.62% yield) safe in my opinion. I like AbbVie below market valuation. I like the dividend even more. On top of that, I have always liked the aggressive management.

The Chart

One quickly sees the failed break-out last week, coming out of a cup with handle pattern. Then again, the stock is a different animal going forward from here. The reasons to be here are valuation, dividend yield and confidence in guidance. It would help in the short-term, if we could see that 50 day SMA ($79.30) curl away from the 200 day SMA ($78.04) without actually making contact. My own level of confidence in this position is strong.

AbbVie 

- Target Price: $103

- Pivot: $85

- Panic: $79

(AbbVie, Abbott Labs and Johnson & Johnson are holdings in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells these stocks? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was Long ABBV, ABT, JNJ equity.

TAGS: Dividends | Drug Approvals | Earnings | Investing | Markets | Options | Stocks | Technical Analysis | Trading | Pharmaceuticals

More from Investing

AMC Is a High Risk, High Reward Play

Timothy Collins
Jan 22, 2021 2:15 PM EST

Short and sweet: This is based on the high running emotions of the markets. There's little to it beyond that.

GoodRx Needs a Shot in the Arm to Improve Its Outlook

Bruce Kamich
Jan 22, 2021 2:03 PM EST

IPOs in recent months have done extremely well -- not so GDRX.

2021 and 2022 Look Difficult for Intel, While 2023 -- Might -- Be Better

Eric Jhonsa
Jan 22, 2021 1:44 PM EST

Competition from AMD and ARM CPU developers looks set to take a toll over the next two years. But Intel could be in better shape in 2023 if its new CEO is ready to make some tough choices.

GameStop and the Dangerous Game of Gamma Squeezes

Timothy Collins
Jan 22, 2021 1:26 PM EST

What happened after Citron Research posted a video about GameStop is very troubling.

Stocks Are Well Off Early Lows, but There's Still Quite a Bit of Weakness

James "Rev Shark" DePorre
Jan 22, 2021 1:18 PM EST

There is still strong interest in stock picking which is the most positive thing about this market.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    I'll discuss price targets in my Saturday column.
  • 07:54 AM EST GARY BERMAN

    Friday Morning Fibocall for 1/22/2021

    SPX (Long-Term View) The 1/21/21 NEW high @ 3861...
  • 11:16 AM EST CHRIS VERSACE

    Worst Stocks to Buy for the Biden Presidency

    Biden's take on the minimum wage, likely moves on ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login